BofA cuts HIMS 2026 GLP-1 revenue forecast to $516 million
- Bad news: BofA cut its 2026 GLP-1 revenue forecast from $577 million to $516 million, revenue lost in the switch to branded drugs.
- Bad news: Q1 consensus EPS is $0.05, down 75% year on year, as branded GLP-1 margins are far below the compounding era.
- Good news: BofA's model has no peptide revenue, so a positive FDA advisory committee signal in July would be pure upside.
Read the full notes
BofA model detail
Allen Lutz
- 2026 GLP-1 revenue revision
Cut from $577 million to $516 million (revenue lost in the switch to branded drugs)
- Peptide blind spot
The model includes no peptide revenue at all. A positive signal from the FDA advisory committee in July would be pure upside to the valuation.
- PT
$21
- Rating
Neutral
Management framework shift
- Change
At its Q4 results, management chose to drop legacy metrics such as 'online revenue per user'
- Interpretation
Management has a clear view of what the next strategic phase looks like
- MerlinTrader view
'HIMS is no longer a single-product bet but a scaled consumer health engine that has been forced to mature faster'
- New framing
An 'integrated revenue platform' (across channels, regions and care models)
Price action
- 17 Apr close
$28.67
- 18 Apr
Market closed for Good Friday
Q1 earnings
- Consensus EPS
$0.05 (-75% YoY)
- Consensus revenue
$619 million (+5.6% YoY)
- Date
11 May, after the close
- Reason for EPS decline
Branded GLP-1 margins are far below those of the compounding era
- Key watchpoints
- How many GLP-1 users convert to branded drugs (BofA expects 40-50%)
- Progress on integrating Eucalyptus (90% of its revenue comes from distributing branded GLP-1s, and it is expected to cut EBITDA margin by 1-2 percentage points)
- New subscriber growth (only +2% QoQ in Q4, currently the biggest worry)
- Early guidance on Labs and peptides
Sources 3
- MerlinTrader in-depth report
- Benzinga
- BofA research